Reyataz(atazanavir)
Atazanavir, Evotaz, Reyataz (atazanavir) is a small molecule pharmaceutical. Atazanavir was first approved as Reyataz on 2003-06-20. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Atazanavir, Reyataz (discontinued: Atazanavir, Reyataz)
CombinationsEvotaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atazanavir sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| REYATAZ | Bristol Myers Squibb | N-021567 RX | 2003-06-20 | 2 products, RLD |
| REYATAZ | Bristol Myers Squibb | N-206352 RX | 2014-06-02 | 1 products, RLD, RS |
Show 1 discontinued
Atazanavir sulfate
+
Cobicistat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EVOTAZ | Bristol Myers Squibb | N-206353 RX | 2015-01-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| atazanavir | ANDA | 2025-06-02 |
| atazanavir sulfate | ANDA | 2025-08-06 |
| evotaz | New Drug Application | 2025-05-12 |
| reyataz | New Drug Application | 2024-12-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE08: Atazanavir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR15: Atazanavir and cobicistat
— J05AR23: Atazanavir and ritonavir
HCPCS
No data
Clinical
Clinical Trials
250 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 21 | 31 | 56 | 40 | 32 | 171 |
| Hiv | D006678 | — | O98.7 | 7 | 5 | 11 | 12 | 14 | 47 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 3 | 9 | 15 | 8 | 9 | 41 |
| Infections | D007239 | EFO_0000544 | — | — | 3 | 5 | 3 | 3 | 14 |
| Healthy volunteers/patients | — | — | — | 9 | — | — | 1 | — | 10 |
| Hepatitis c | D006526 | — | B19.2 | 2 | 4 | 3 | 2 | 1 | 10 |
| Hiv-1 | D015497 | — | — | 2 | 3 | 2 | 2 | 2 | 10 |
| Lipodystrophy | D008060 | — | E88.1 | — | — | — | 3 | 1 | 4 |
| Drug interactions | D004347 | — | — | — | — | — | 1 | 2 | 3 |
| Highly active antiretroviral therapy | D023241 | — | — | — | — | — | 1 | 1 | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 2 | 2 | — | 1 | 5 |
| Hepatitis | D006505 | — | K75.9 | — | 2 | 2 | — | 1 | 5 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | 1 | — | 3 | 4 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | 1 | 2 | — | 1 | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | 3 | 2 | — | — | 3 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | 1 | 3 | — | — | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 2 | 1 | — | — | 2 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | 2 | 1 | — | — | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 1 | — | — | 2 |
| Hepatitis b | D006509 | — | — | — | 1 | 1 | — | 1 | 2 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ebola hemorrhagic fever | D019142 | EFO_0007243 | A98.4 | — | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | — | — | — | 1 |
| Viremia | D014766 | — | B34.9 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | — | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperbilirubinemia | D006932 | — | — | — | — | — | — | 1 | 1 |
| Nephrolithiasis | D053040 | — | N20.0 | — | — | — | — | 1 | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 1 | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
| Genital diseases | D000091662 | — | — | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Atazanavir |
| INN | atazanavir |
| Description | Atazanavir is a heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV). It has a role as an antiviral drug and a HIV protease inhibitor. |
| Classification | Small molecule |
| Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C |
Identifiers
| PDB | — |
| CAS-ID | 198904-31-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1163 |
| ChEBI ID | 37924 |
| PubChem CID | 148192 |
| DrugBank | DB01072 |
| UNII ID | QZU4H47A3S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Reyataz – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atazanavir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,198 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use